Up-front therapy for patients with renal failureUp-front therapy for patients with renal failure
Editor's comments
A critical and emergent clinical scenario in myeloma management is a patient presenting with the disease in acute renal failure. The 2 most common initial therapies used are CyBorD (the choice of both faculty) and bortezomib/dexamethasone. Dr Vij notes that data from nonrandomized studies suggest that reversal of renal dysfunction within the first few months allows patients to live nearly as long as those who started out with normal renal function, and for this reason he approaches these cases aggressively with a 3-drug regimen. |